Portfolio company
Caspian Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops small-molecule menin inhibitors to restore insulin production in patients with diabetes and cardiometabolic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Zucara Therapeutics
This company develops a drug therapy to prevent hypoglycemia in patients with type 1 diabetes using insulin therapy.
DiogenX
This biotech company develops recombinant proteins designed to regenerate insulin-producing pancreatic beta cells for patients with type 1 diabetes.
Encellin
The company develops an encapsulated cell replacement therapy to deliver living medicines for patients with endocrine disorders such as type 1 diabetes.
Caldan Therapeutics
The company develops small-molecule drugs targeting free fatty acid receptors to treat metabolic diseases, such as type 2 diabetes, for the pharmaceutical industry.
Calyx Therapeutics
This company develops oral therapies for diabetes and inflammatory diseases using natural plant extracts for pharmaceutical and biotechnology organisations.
Foventa Therapeutics
The company develops non-invasive topical eye drops to treat retinal vascular diseases for patients with non-proliferative diabetic retinopathy.
CasInvent Pharma
This company develops small molecule inhibitors targeting casein kinase 1 enzymes to treat patients with treatment-resistant cancers such as acute myeloid leukaemia and melanoma.
AdipoPharma
This clinical-stage biotechnology company develops therapeutic peptides to treat insulin resistance and type 2 diabetes for patients with metabolic disorders.